KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Net Margin (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Net Margin for 10 consecutive years, with 18884.26% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 1866284.0% to 18884.26% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 17496.5% through Dec 2025, down 1640312.0% year-over-year, with the annual reading at 17496.47% for FY2025, 1640313.0% down from the prior year.
  • Net Margin hit 18884.26% in Q4 2025 for CRISPR Therapeutics AG, down from 11970.98% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 84.3% in Q2 2021 to a low of 1881766.67% in Q4 2022.
  • Historically, Net Margin has averaged 125085.99% across 5 years, with a median of 15722.08% in 2025.
  • Biggest five-year swings in Net Margin: crashed -187777810bps in 2022 and later surged 188181109bps in 2023.
  • Year by year, Net Margin stood at 3988.57% in 2021, then tumbled by -47079bps to 1881766.67% in 2022, then surged by 100bps to 44.43% in 2023, then plummeted by -598bps to 221.42% in 2024, then crashed by -8429bps to 18884.26% in 2025.
  • Business Quant data shows Net Margin for CRSP at 18884.26% in Q4 2025, 11970.98% in Q3 2025, and 23379.93% in Q2 2025.